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S302 Poster Session IResults: Sixteen of 17 evaluable patients have engrafted (one is too
early to evaluate). Early toxicity data is available for 16 patients
and include: oral mucositis (maximum grade 3), hypertension (max-
imum grade 3), and hyperbilirubinemia (N5 3). One patient devel-
oped hepatic veno-occlusive disease, after which the busulfan goal
level on pharmacokinetic analysis was reduced to keep a lower steady
state concentration target. After this adjustment, there have been no
further occurrences of VOD. Infections included: CMV viremia
(N 5 2), influenza A (N 5 1), clostridium difficile (N 5 1), bacter-
emia (N 5 1) and clostridium botulinum (N 5 1). To date, 14 of
the 17 patients are alive and disease-free at a median follow up of 6
months (range 0.3 – 28months). Cause of death for the three patients
was multi-organ failure (N 5 1), infection (N 5 1), and severe pul-
monary hypertension (N 5 1).
Table 1. Patient and donor characteristics
Characteristics Number or Median (Range)Table 1.
Patients tested (n)
Overall prevalence (n;%) 23/63 (3
Viremia only (n;%) 5/63 (8
Invasive disease (n;%) 6/63 (1
Stoll only (n;%) 11/63 (1
Median viral load (copies/ml) 2,189 (6Patients
Total no. of patients 17
Males 9
Females 8
Age (years) 8 (5-27)
Transplant indication
Severe Single lineage cytopenia 2
Aplastic anemia 12
MDS - refractory anemia 2
refractory anemia with excess blasts 1
Prior treatments
Transfusions 16
Androgens 8
Prior infections 6
Donors
Related 5
(parental 8/8, 6/8, 5/8 (N 5 2) and 4/8
matched donors)
Unrelated 12
(8/8 matched n5 11 and 7/8 matched N5 1)Conclusion: In this interim study report, engraftment, early toxicity
and infection data appear to be similar to historical TBI-based pro-
tocols with no graft failures to date. Although the study is ongoing
with planned accrual of 25 total patients, these results appear prom-
ising and suggest that such alternative donor HSCT can be effec-
tively performed without radiation.
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Background: Viral infections are a known cause of morbidity and
mortality in patients receiving allogenic hematopoietic stem cell
transplantation (SCT), however limited data has been reported in
pediatric patients undergoing autologous transplant. The aim of
this retrospective study was to evaluate the prevalence and outcomeAD V CM
63 63
5%) 6/63 (10%
%) 3/63 (5%)
0%) 3/63 (5%)
7%) 0
45-142,300) 15,567 (2,66of viral infections in children undergoing autologous SCT
(auto-SCT).
Methods: Between January 2004 and July 2011 a total of 140 autol-
ogous transplants were performed for malignant diseases in 90
patients. Patients who were seropositive for cytomegalovirus
(CMV) or Epstein-Barr virus (EBV) were monitored with blood
polymerase chain reaction (PCR) weekly. Adenovirus (ADV) weekly
blood monitoring by PCR was initiated in 2007. Polyoma BK virus
(BKV) virus testing was done as clinically indicated for hematuria
and if positive, monitoring for viremia was initiated. Viremia was de-
fined as the presence of virus in blood above detectable level on quan-
titative PCR. Invasive disease was defined as virus detection at least
in two different organ systems. Patients with hypogammaglobulin-
emia received intravenous immunoglobulin supplementation to
maintain nornal for age IGG level.
Results: Sixty four of 90 patients were tested for viruses. Twenty
nine of the tested patients had viruses detected, with 10 patients hav-
ing more than one virus. Table 1 summarizes the prevalence of vi-
remia and viral infections. Most prevelant virus was adenovirus,
presenting as either enteritis or invasive disease. CMV or EBV
pneumonitis was diagnosed in 3 symptomatic patients. Three pa-
tients developed virus-associated thrombotic microangiopathy re-
sulting in renal failure in 2 patients. Viral infection was a cause of
death in 2% (2/90) of all patients undergoing auto-SCT or in 3%
(2/64) of patients who were tested for viruses.
Conclusion: In our patient cohort serious viral infections were rare.
Even in the presence of invasive disease mortality was low. Data sug-
gests that routine viral screening is not neccesary for all patients un-
dergoing auto-SCT, however symptomatic patients should be
evaluated promptly.265
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Background: Stem cell transplantation has been highly successful
for poor-risk SCD but only 14-18% of patients have an HLA-
matched unaffected sibling (Bhatia/Walters, BMT, 2008). Alternate
allogeneic donors include unrelated adult donors and unrelated cord
blood donors (Cairo et al., BBMT, 2008). Due to patient demo-
graphics matched unrelated adult donors are limited in the registries
and results of unrelated UCB transplants have been dismal to date.
(Bhatia/Cairo et al., ASBMT, 2010 and CTN 0601)
FHI TCD AlloSCT is an alternative that could greatly improve
outcomes in these patients. A recent phase II trial in high-risk leuke-
mia patients utilized CliniMACS (Miltenyi Biotec) one step CD34+
selection, and demonstrated a median recovery of CD34+ cells of
79%, median T-cell depletion of 4.5log, 94/101 patients engrafted
with aGVHD in only 8/100 patients. (Aversa et al.,JCO, 2005) Min-
imal-intensity conditioning followed by FHI TCD in high risk thal-
assemia patients achieved engraftment in 16/22 patients without
aGVHD and 90% OS. (Sodani et al., Blood, 2010)
Objective: This study seeks to employ a similar approach in high-
risk SCD patients.V EBV BK
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) 9/58 (16%) 2/5 (40%)
6/58 (10%) 0
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5-61,600) 1,302 (647-7,207) 125,540 (50,520-44x10^6)
